人用藥品歐洲公共評估報告 (EPAR)：Mulpleo（原名 Lusutrombopag Shionogi），lusutrombopag，授權日期：2019年2月18日，修訂版：9，狀態：已撤回
On 14 April 2026, the European Commission withdrew the marketing authorisation for Mulpleo (lusu…
正文內容
On 14 April 2026, the European Commission withdrew the marketing authorisation for Mulpleo (lusutrombopag) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Shionogi B. V. , which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. Mulpleo was granted marketing authorisation in the EU on 18 February 2019 to prevent excessive bleeding in adults with thrombocytopenia due to long-standing liver disease. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2023. News on Mulpleo (previously Lusutrombopag Shionogi) Application under evaluation European Commission decision Mulpleo is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease undergoing invasive procedures This medicine's authorisation has been withdrawn This medicine’s product information is available in all official EU languages. Select 'available languages' to access the language you need. Product information documents contain: English (EN) (95.09 KB – PDF) English (EN) (83.73 KB – PDF) English (EN) (648.96 KB – PDF) summary of product characteristics (annex I);
manufacturing authorisation holder responsible for batch release (annex IIA); conditions of the marketing authorisation (annex IIB);
package leaflet (annex IIIB). English (EN) (26.9 KB – PDF) Herengracht 4641017 CAAmsterdamThe Netherlands Mulpleo: EPAR – Medicine overview Lusutrombopag Shionogi: EPAR – Risk-management-plan summary Mulpleo: EPAR – Product information Mulpleo (previously Lusutrombopag Shionogi): EPAR – All authorised presentations български (BG) (125.14 KB – PDF) español (ES) (93.83 KB – PDF) čeština (CS) (118.08 KB – PDF) Deutsch (DE) (94.28 KB – PDF) ελληνικά (EL) (131.96 KB – PDF) français (FR) (94.17 KB – PDF) hrvatski (HR) (113.83 KB – PDF) italiano (IT) (92.96 KB – PDF) latviešu (LV) (119.27 KB – PDF) lietuvių (LT) (117.04 KB – PDF)
文章相關商品
系統已根據文章標題、摘要和正文，自動匹配目前在售的強相關藥品。
蘆曲泊帕片 LUTRODX Lusutrombopag
蘆曲泊帕（Lusutrombopag）是一種口服小分子血小板生成素受體激動劑（TPO-RA），透過作用於人類血小板生成素（TPO）受體的跨膜結構域，與內源性TPO相同的方式活化訊號傳導路徑，促進血小板生成。其無需注射和劑量滴定，使用便捷，不受藥物交互作用影響，不受食物狀態影響。
查看商品
常見問題
Which products are related to this article?
The system matched these relevant products from the article content: 盧修斯 蘆曲泊帕 Lusutrombopag 線上購買、蘆曲泊帕片 LUTRODX Lusutrombopag.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.
